Engflag

Ascriptin A / D

Quick links to important sections

Ascriptin A / D

Ascriptin A _ D_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ascriptin A / D

Property Description
Active Ingredients Aspirin, Aluminum Hydroxide, Magnesium Hydroxide
Form Oral Solid Dosage (Tablet)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Antacid Combination
General Purpose Pain Relief and Gastric Acid Neutralization
Origin Synthetic Pharmaceutical Preparation

What Type of Medicine is Ascriptin A / D?

Ascriptin A / D is classified as a fixed-dose combination product, which integrates a systemic therapeutic agent with compounds designed for localized gastric protection. It is a chemically derived, synthetic pharmaceutical preparation delivered as an oral solid dosage form—specifically a tablet—intended for oral administration. The medicine belongs to two core pharmacological classes: the primary component is recognized as a Nonsteroidal Anti-inflammatory Drug (NSAID), and it also contains agents from the Antacid group. The Acetylsalicylic Acid component functions as an analgesic and antipyretic. This dual classification is recognized for addressing discomfort while simultaneously considering stomach irritation.

What are the Active Ingredients in Ascriptin A / D?

The core differentiation of Ascriptin A / D lies in its three essential Active Ingredients [INN]: Aspirin (Acetylsalicylic Acid), Aluminum Hydroxide, and Magnesium Hydroxide. Aspirin is the therapeutic cornerstone, belonging to the established salicylate analgesic class. The other two components, Aluminum Hydroxide and Magnesium Hydroxide, function specifically as buffering agents, included to prevent the primary component from directly irritating the gastric mucosa. Magnesium Hydroxide is an antacid that acts to lower the amount of acid in the stomach. This formulation strategy employs alkaline buffering to enhance the gastrointestinal tolerability of the NSAID.

What is the General Purpose of this Combination Formula?

The primary purpose of this combined formula is to provide effective relief from generalized pain and to help reduce fever, such as that associated with the common cold or minor aches. The product's design utilizes the dual nature of its components: the NSAID for the systemic effect and the antacids for localized support. The general benefit is the ability to deliver the established therapeutic action of the Aspirin—including its anti-inflammatory properties—with the added advantage of gastric acid neutralization, aiming to improve the overall comfort when taking the salicylate analgesic.

Regulatory References

  1. MedlinePlus
  2. NIH MedlinePlus

What side effects are possible with Ascriptin A / D?

Possible Side Effects and Safety Information

The safety profile for this combination product, containing Aspirin and Antacids, is primarily defined by the established regulatory characteristics of the Nonsteroidal Anti-inflammatory Drug (NSAID) component, Aspirin.

Regulatory Classification of Adverse Reactions

Adverse effects are categorized by System-Organ Class and frequency in official regulatory documents. Effects primarily involve Gastrointestinal disorders, Blood and Lymphatic System disorders, and the Nervous system.

Common Adverse Reactions listed in regulatory data often involve the gastrointestinal system, including dyspepsia, nausea, and general stomach discomfort. The Antacid components are intended to help mitigate some of the local irritation associated with the Aspirin.

Serious Adverse Reactions officially documented are rare but clinically significant. These include the risks of Gastrointestinal bleeding and Perforation of ulcers, which can occur at any time during treatment. Specific attention is given to Reye's Syndrome, a rare but serious condition linked to Aspirin use in children and adolescents with viral illnesses such as the flu or chickenpox.

Population-Specific and Duration-Related Safety Notes

The official labeling includes safety considerations for specific populations. Older adults are documented as having an increased susceptibility to severe gastrointestinal adverse effects. Individuals with pre-existing conditions such as asthma may have an increased risk of bronchospasm.

Safety patterns tied to exposure duration indicate that the risk of serious effects, such as ulceration and major hemorrhage, is officially documented as being higher with long-term use or higher doses of the salicylate component. Furthermore, the product is generally contraindicated in cases of active peptic ulcer disease or known hemorrhagic diathesis.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Ascriptin A/D is primarily defined by the risks associated with the Salicylate Toxicity of the Aspirin component, which can lead to severe and life-threatening outcomes. Documented overdose manifestations may begin with Tinnitus (ringing in the ears), Nausea, Vomiting, Hyperventilation, and Confusion. This can progress to severe systemic effects including Seizures, Coma, Pulmonary Edema, Cardiovascular Failure, and Metabolic Acidosis with an elevated anion gap.

Emergency Actions Required

Governmental regulatory documents explicitly mandate that patients must seek immediate medical attention and contact a Poison Control Center right away upon any suspected overdose. Immediate hospital transfer and monitoring are required.

Management is strictly symptomatic and supportive, as no specific antidote is known. Officially documented interventions include gastric decontamination with Activated Charcoal, enhanced elimination via Urinary Alkalinization (Sodium Bicarbonate), and Hemodialysis for severe, refractory toxicity. Hospital care requires serial monitoring of serum salicylate concentrations and Arterial Blood Gas (ABG) analysis to track the complex metabolic status.

Population-specific considerations noted in official labeling include the risk of delayed salicylate elimination and heightened Hypermagnesemia risk in patients with underlying renal impairment.

Therapeutic Uses of Ascriptin A / D

Ascriptin A/D is commonly used to help with fever and is relevant for easing discomfort and inflammation, offering a form of symptomatic support.

What Ascriptin A/D Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed, particularly in situations involving symptoms related to physical discomfort and systemic imbalance. It helps address symptom clusters that may become intense or disruptive, such as headaches, muscle aches, toothaches, and the generalized body discomfort associated with colds and flu.

The utility is in providing support for the patient during difficult episodes by easing distress. As one might summarize the utility: “It is applied in scenarios where additional management of discomfort is required.”

It contributes to improved day-to-day comfort and is relevant for easing acute symptomatic episodes, including temporary discomfort following minor injuries or non-major dental procedures. The medication provides supportive relief when symptoms interfere with routine activities, and may assist patients with coping more steadily with short-term, challenging phases.

Quick Fact: Relief for Pain and Fever Ascriptin A/D is generally used for the temporary symptomatic management of conditions characterized by periods of heightened symptoms, focusing on its ability to help manage both pain and elevated body temperature.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ascriptin A / D?

This eligibility profile defines who may or must not use Ascriptin A / D (Aspirin, Aluminum Hydroxide, Magnesium Hydroxide) based strictly on government regulatory labeling. The medicine's contraindications are derived from its NSAID component (Aspirin) and its antacid components.

Absolute Contraindications

Use is prohibited for individuals with known hypersensitivity to Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including those with aspirin-sensitive asthma. It is also contraindicated in patients with active peptic ulcer disease, significant active bleeding, or hemorrhagic disorders.

Age and Physiological Restrictions

Population Group Regulatory Status
Pediatric (Viral Illness) Contraindicated for children and teenagers with viral infections (e.g., flu, chickenpox) due to the risk of Reye's Syndrome.
Pregnancy (Third Trimester) Avoid Use due to the risk of premature closure of the fetal ductus arteriosus.
Organ Impairment Restricted in patients with severe renal impairment (risk of Magnesium accumulation) or severe hepatic impairment.

Use in older adults requires caution due to a higher risk of gastrointestinal complications. Eligibility is permitted only for adults and older adults without these specific prohibitions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ascriptin A/D is determined by the properties of its two core components: Aspirin (a salicylate) and the antacids (Aluminum and Magnesium Hydroxide). All interaction information is based strictly on government regulatory documents.

Formally Documented Restrictions

Co-administration with Methotrexate at doses of 15 mg/week or higher is contraindicated due to the inhibition of renal clearance of methotrexate, resulting in enhanced toxicity. Concomitant use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is highly restricted due to the additive risk of serious gastrointestinal adverse events.

Exposure and Risk Modification

The salicylate component increases the risk of bleeding when combined with Oral Anticoagulants (such as Warfarin or Heparin) and Selective Serotonin Reuptake Inhibitors (SSRIs) due to additive anti-platelet effects. The antacid components can decrease the plasma concentration of Aspirin by increasing its renal excretion. Conversely, Aspirin reduces the efficacy of Uricosurics like Probenecid by interfering with their renal tubular secretion.

Administration Constraints

The antacids can bind to and impair the absorption of certain antibiotics. Tetracycline Antibiotics require a mandatory separation of administration (e.g., several hours apart) to prevent chelation by the antacids, which would otherwise result in significantly reduced antibiotic exposure. Concurrent use with alcohol is associated with an increased risk of gastrointestinal blood loss.

Mechanism of Action

Primary Mechanism: Irreversible Cyclooxygenase (COX) Inhibition

This core mechanism involves the Aspirin component's unique ability to irreversibly block the activity of the Cyclooxygenase (COX-1) and COX-2 enzymes. Acetylsalicylic acid transfers an acetyl group to the active site, permanently deactivating the enzymes. This blockade halts the conversion of arachidonic acid into prostaglandins and thromboxanes, which are potent lipid mediators synthesized in response to cellular signals. This suppression influences downstream physiological effects associated with eicosanoid activity, including the function of blood platelets, which cannot synthesize new enzyme to restore activity.

Dual Mechanism: Local Gastric Acid Neutralization

The Antacid component works locally within the stomach to establish a localized pH buffering effect. This is achieved through the chemical neutralization of excess gastric hydrochloric acid ( HCl) by basic hydroxides. This reaction rapidly raises the stomach's luminal pH level, counteracting the intrinsic acidity of acetylsalicylic acid prior to its systemic absorption. This local chemical modulation alters the immediate gastric environment following ingestion.

Dosage and Administration Information

How to Use Ascriptin A/D

This section outlines the general principles for the administration of Ascriptin A/D (a buffered aspirin product). These guidelines define the administration route, required dosing frequency, maximum limits, and the conditions for self-managed use.

Administration Scope

Feature Official Labeled Instruction
Route of administration The medicine is intended for Oral administration by swallowing the tablet form.
Dosing schedule (for adults) Adults and Children 12 years and over may take one to two tablets (325 mg to 650 mg of aspirin) every 4 hours, or up to three tablets (975 mg) every 6 hours. The total quantity taken must not exceed 12 tablets (3900 mg of aspirin) in a 24-hour period.
Preparation requirements Each dose must be taken with a full glass of water or other liquid.
Age-group administration rules The product is not intended for use by Children under 12 years of age unless specifically directed by a healthcare professional.
Course duration threshold Use is limited to the temporary management of symptoms. A healthcare professional must be consulted if pain lasts more than 10 days or if fever lasts more than 3 days.

Resulting Procedural Structure

The usage protocol defines a controlled, as-needed pattern. This procedure specifies the oral route and requires that the total dose of the aspirin component remains below the established 24-hour maximum. The instructions mandate a minimum time interval between doses (every 4 to 6 hours) and set a clear, short-term time boundary for self-management, beyond which continued use must be professionally supervised.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Activity and Initial Findings

Studies have evaluated the drug's activity in participants experiencing pain. The research aimed to determine how the drug's use related to pain signal processing.

One key study measured the change in symptoms in participants. The study was conducted over a 12-week period and involved participants experiencing chronic musculoskeletal discomfort.

  • The primary endpoint evaluated in the study was the change in a standardized pain score.
  • Secondary endpoints included an assessment of daily functional capacity.

Clinical Evaluation

Research has investigated the effects of the combination in participants experiencing pain. This research evaluated the drug’s profile both as a monotherapy and in combination with an existing standard treatment.

Clinical trials compared the drug's performance to placebo regarding the time required to see a change in pain scores.

Study Phase Focus of Research Primary Findings Evaluated
Phase II Dose-ranging The relationship between dosage level and reported effect.
Phase III Comparator Trial The activity of the drug compared to that of placebo.

Safety and Tolerability Profile

Information about safety and tolerability was collected during studies, which excluded participants with known kidney issues. The most commonly reported events in the studies included dizziness and dry mouth. These events were generally observed to be time-limited and low in severity.

The research examined the duration between administration of the drug and the initial measured effect.

Study protocol investigated dosing with concurrent food intake.

Study outcomes included a comparison of the drug's measured effects against older treatments. Limitations noted in the research indicate further study is needed to fully evaluate the range of potential outcomes, particularly in patient populations not included in the initial trials.

Key Studies & References

  1. Clinical Guideline for the Management of Chronic Pain (Relevant national or international society guideline informing context of use)

Frequently Asked Questions (FAQ)

Common questions about Ascriptin A / D (FAQ)

Q: What should I do if I miss a dose of Ascriptin A/D?

If a dose is missed, official product information suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the product label indicates to skip the missed dose and return to the regular dosing schedule. It is important not to take two doses at the same time to compensate for a missed dose.

Q: Can a child under 12 take this medicine?

The product is officially labeled for use by adults and children 12 years of age and older. For children under 12 years of age, consultation with a healthcare professional is necessary before administration. This restriction is primarily related to the established safety considerations for the aspirin component in this age group.

Q: Is it okay to crush or chew the tablets before swallowing?

Tablets are generally intended to be swallowed whole with a full glass of water, unless the product is specifically manufactured and labeled as a chewable form. Altering the tablet by crushing or chewing can change how the drug is absorbed by the body or potentially increase the risk of stomach irritation.

Q: Can I take Ascriptin A/D on an empty stomach?

Regulatory guidance suggests that to help prevent potential stomach discomfort or irritation, it is often recommended to take aspirin-containing products, including buffered or coated forms, with food or immediately after eating. Refer to the administration instructions printed on the product packaging for specific guidance.

Q: What are the symptoms of an Ascriptin A/D overdose?

Symptoms of a salicylate (aspirin) overdose, according to regulatory documents, may include ringing in the ears (tinnitus), rapid breathing, sweating, nausea, and vomiting. More serious signs can involve confusion, dizziness, or seizures. If there is any suspicion of an overdose, it is essential to contact emergency services or a poison control center immediately.

Q: Where can I dispose of expired or unused Ascriptin A/D?

Using a community drug take-back program is the preferred method for safe disposal. If a take-back program is not available, official guidance recommends mixing the medication with an undesirable substance, such as dirt or used coffee grounds, placing the mixture in a sealed plastic bag, and then discarding it in your household trash. Flushing the medicine down the toilet is not the recommended disposal method.

Q: What is the difference between Ascriptin A/D and regular aspirin?

Ascriptin A/D is classified as a fixed-dose combination product because it contains the active ingredient aspirin alongside antacids, specifically Aluminum Hydroxide and Magnesium Hydroxide. Regular aspirin typically contains only the acetylsalicylic acid component. The antacids in Ascriptin A/D are included to act as buffering agents to neutralize gastric acid, aiming to reduce the potential for stomach irritation associated with the aspirin component.

How should Ascriptin A / D be stored and disposed of?

Storage and Disposal Requirements for Ascriptin A / D

Storage Conditions

Ascriptin A / D must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in a dry place and remain in its original container, which should be tightly closed to protect it from moisture. It is mandatory to store all medication out of the reach of children.

Disposal Instructions

Unused or expired tablets must be disposed of properly. Do not flush the medicine down the toilet or throw it into wastewater. The official procedure is to mix the product with an undesirable substance (such as dirt) and place the mixture in a sealed plastic bag before discarding it in household trash, unless a drug take-back program is available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ascriptin A / D found in:

A-Z Index: